Salix Pharmaceuticals Receives Approvable Letter from FDA for Balsalazide Tablet
pharmiweb.co.uk: RALEIGH, N.C. - Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has received an approvable letter from the U.S. Food and Drug Administration (FDA) for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and pharmiweb.co.uk
pharmiweb.co.uk     May 17, 2008            

RALEIGH, N.C. - (Business Wire) Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has received an approvable letter from the U.S. Food and Drug Administration (FDA) for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18... [read full story]                    


View all news articles about*:
America Carolina North Pharmaceuticals Raleigh Salix States United
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

Salix Pharmaceuticals to Present at Thomas Weisel Partners Conference (Business Wire)

yahoo.com     Aug 28, 2008   3 related          

Thursday August 28, 7:00 am ET RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP - News ) today announced that the Company will present at the Thomas Weisel Partners Healthcare Conference 2008 in...                    

comments

Salix Pharmaceuticals closes sale of $60M debt

ibtimes.com     Aug 22, 2008   2 related          

Salix Pharmaceuticals Ltd. said Friday it closed its offering of $60 million in debt. The company, which makes pharmaceutical products to treat gastrointestinal disease, said the sale of the 5.5 percent convertible senior...                    

comments

                   

InPlay: Home Depot beats by $0.10, beats on revs (Briefing.com)

yahoo.com     Aug 19, 2008          

6:05AM GigaMedia appoints Quincy Tang as Chief Financial Officer 12.63 : 6:03AM Home Depot beats by $0.10, beats on revs 26.96 : Reports Q2 (Jul) earnings of $0.71 per share, $0.10 better than the First Call consensus of $0.61;...                    

comments

Salix Pharma offers $55 million in senior notes

ibtimes.com     Aug 19, 2008   16 related          

Salix Pharmaceuticals Ltd., a drug developer, said late Monday it priced an offering of $55 million in convertible senior notes due 2028. Salix, which focuses on gastrointestinal diseases, plans to use proceeds from the sale of...                    

comments